Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.

Bo Y, Guo G, Yao W.

J Neurooncol. 2013 Mar;112(1):27-37. doi: 10.1007/s11060-012-1033-y. Epub 2013 Jan 22.

PMID:
23338605
2.

microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer.

Zhao Y, Li Y, Wang L, Yang H, Wang Q, Qi H, Li S, Zhou P, Liang P, Wang Q, Li X.

J Exp Clin Cancer Res. 2013 Feb 26;32:10. doi: 10.1186/1756-9966-32-10.

3.

Tumor necrosis factor-related apoptosis-inducing ligand induces cytotoxicity specific to osteosarcoma by microRNA response elements.

Xiao F, Chen J, Lian C, Han P, Zhang C.

Mol Med Rep. 2015 Jan;11(1):739-45. doi: 10.3892/mmr.2014.2710. Epub 2014 Oct 20.

PMID:
25335093
4.

Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122.

Yan Y, Zhang F, Fan Q, Li X, Zhou K.

Neoplasma. 2014;61(6):672-9. doi: 10.4149/neo_2014_082.

PMID:
25150312
5.

MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells.

Huo W, Jin N, Fan L, Wang W.

Mol Cell Biochem. 2014 Mar;388(1-2):123-33. doi: 10.1007/s11010-013-1904-3. Epub 2013 Nov 30.

PMID:
24292881
6.

Selective TRAIL-induced cytotoxicity to lung cancer cells mediated by miRNA response elements.

Wu G, Ji Z, Li H, Lei Y, Jin X, Yu Y, Sun M.

Cell Biochem Funct. 2014 Oct;32(7):547-56. doi: 10.1002/cbf.3042. Epub 2014 Aug 1.

PMID:
25132116
7.

Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.

Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.

Neurosurgery. 2009 Sep;65(3):610-24; discussion 624. doi: 10.1227/01.NEU.0000350227.61132.A7.

PMID:
19687708
8.

Selective expression of tumor necrosis factor-related apoptosis-inducing ligand mediated by microRNA suppresses renal carcinoma growth.

Zhang Z, Zhang H, Li H, Chen X, Liu M, Liu D, Zhao Y, Kong X.

Mol Cell Biochem. 2014 Jul;392(1-2):125-34. doi: 10.1007/s11010-014-2025-3. Epub 2014 May 1.

PMID:
24788726
10.

Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.

Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, Condorelli G.

Oncogene. 2013 Aug 22;32(34):4001-8. doi: 10.1038/onc.2012.410. Epub 2012 Sep 10.

PMID:
22964638
11.

MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.

Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K.

Cancer Res. 2007 Oct 1;67(19):8994-9000.

12.

Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.

Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B.

Cancer Res. 2001 Apr 15;61(8):3330-8.

13.

BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.

Burton TR, Henson ES, Azad MB, Brown M, Eisenstat DD, Gibson SB.

Cell Death Dis. 2013 Apr 11;4:e587. doi: 10.1038/cddis.2013.100.

14.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.

Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.

Neurosurg Focus. 2002 Sep 15;13(3):ecp1.

PMID:
15844877
15.

Cancer gene therapy using a novel secretable trimeric TRAIL.

Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.

Gene Ther. 2006 Feb;13(4):330-8.

PMID:
16195699
16.

Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells.

Liu J, Ma L, Li C, Zhang Z, Yang G, Zhang W.

Mol Oncol. 2013 Dec;7(6):1043-55. doi: 10.1016/j.molonc.2013.08.003. Epub 2013 Aug 16.

17.

Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma.

Naumann U, Waltereit R, Schulz JB, Weller M.

J Neurooncol. 2003 Jan;61(1):7-15.

PMID:
12587790
18.

NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.

Aydin C, Sanlioglu AD, Bisgin A, Yoldas B, Dertsiz L, Karacay B, Griffith TS, Sanlioglu S.

BMC Cancer. 2010 Oct 27;10:584. doi: 10.1186/1471-2407-10-584.

19.

Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122.

Zhou K, Yan Y, Zhao S.

Tumour Biol. 2014 Jun;35(6):5787-95.

PMID:
24659424
20.

Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.

Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY.

Cancer Gene Ther. 2003 Nov;10(11):814-22.

PMID:
14605667

Supplemental Content

Support Center